References
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1--34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
- Orwoll E, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
- Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006;7:113-21
- Adachi JD, Hanley DA, Lorraine JK, et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 2007;29:2055-67
- Myers H, Nicholls E, Handy J, et al. The Clinical Assessment Study of the Hand (CAS-HA): a prospective study of musculoskeletal hand problems in the general population. BMC Musculoskelet Disord 2007;8:85
- Rosenberg EA, Sperazza LC. The visually impaired patient. Am Fam Physician 2008;77:1431-6
- Fox C, McKinnon C, Wall A, et al. Ability to handle, and patient preference for, insulin delivery devices in visually impaired patients with type 2 diabetes. Pract Diabetes Int 2002;19:104-7
- Anderson RT, Ory M, Cohen S, et al. Issues of aging and adherence to health interventions. Control Clin Trials 2000;21(Suppl):171-83S
- Halbreich U, Lumley LA, Palter S, et al. Possible acceleration of age effects on cognition following menopause. J Psychiatr Res 1995;29:153-63
- Small SA, Stern Y, Tang M, et al. Selective decline in memory function among healthy elderly. Neurology 1999;52:1392-6
- Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S18-24
- Asakura T, Seino H, Jensen KH. Patient acceptance and issues of education of two durable insulin pen devices. Diabetes Technol Ther 2008;10:299-304
- Kivitz A, Segurado OG. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Rev Med Devices 2007;4:109-16
- Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-56
- Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-100
- Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25
- Lindsay R, Miller P, Pohl G, et al. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2008;20:943-8